Investigating heart problems caused by carfilzomib in cancer patients
A Multi-omics evaluation of Carfilzomib-related Cardiotoxicity
This study is looking at how the cancer treatment carfilzomib might affect heart health in people with multiple myeloma, and it aims to find ways to predict and prevent heart problems before treatment starts.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10880672 on NIH RePORTER |
What this research studies
This research focuses on understanding the heart-related side effects, specifically heart failure, that can occur in patients with multiple myeloma who are treated with the drug carfilzomib. By using a multi-omics approach, which includes analyzing genetic and metabolic data, the study aims to identify specific biomarkers that can predict which patients are at higher risk for these adverse effects. The goal is to develop personalized strategies to prevent or reduce the risk of cardiotoxicity before patients receive treatment. This could lead to better management of heart health in cancer patients undergoing therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are being considered for treatment with carfilzomib.
Not a fit: Patients who are not undergoing treatment with carfilzomib or those with other types of cancer unrelated to multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cardiovascular outcomes for cancer patients receiving carfilzomib, enhancing their overall treatment experience and quality of life.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for cardiotoxicity in cancer treatments, suggesting that this approach may yield valuable insights.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Gong, Yan — University of Florida
- Study coordinator: Gong, Yan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.